Could your next stem cell recovery happen at home?
NCT ID NCT02671448
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study looks at whether people with plasma cell disorders can safely recover from an autologous stem cell transplant at home instead of in the hospital. Researchers want to see if home recovery is practical, reduces infections, and keeps patients satisfied. About 91 adults aged 18 to 80 who live in certain areas or at the MSK Residence can join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
83 people
The number who actually took part.
- Start date
-
Jan 2016
- Expected to finish
-
Jan 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of Plasma cell dyscrasia * Treatment plan including Autologous HSCT * 18-80 years of age * Appropriate homebound setting as defined by one of the following: * Lodging at the MSK Residence. * Staying at home or a "home equivalent" in any one of the zip codes as outlined in the appendix. Home equivalent is defined as a residence which may or may not be the primary residence of the patient. * "Home equivalent" must pass the "Home Environment Screening Tool" for homebound stem cell transplantation (not required for other MSK recognized lodging facility). * Adequate caregiver support as defined by: * Single or multiple informal caregivers willing and able to provide 24 hour a day, seven day a week supervision of the transplant recipient in their home or "home-like" environment. * Caregiver willing and able to fulfill the basic stem cell transplant caregiver education requirements as determined by caregiver and healthcare team, including social worker * Have Wi-Fi connection * Appropriate third party payer coverage for "Homebound Stem Cell Transplant Program" * Both patient and caregiver willing to give and sign informed consent. Exclusion Criteria: * Patients with a documented active infection prior to starting their preparative regimen. This includes grade 3 or higher viral, bacterial, or fungal infection. * Uncontrolled arrhythmias * Active or uncontrolled pulmonary disease * Karnofsky Performance Scale (KPS) score \<80 * Sorror Co-morbidity index ≥ 4 except in patients with history of resected cancers * Creatinine clearance (calculated or measured) of \< 50 cc/minute * Inability of patient or caregiver to speak or read English (we currently do not have the manpower to translate nor staff a multilingual homebound stem cell transplant program with adequate educational materials). * Inadequate housing arrangements * Inadequate caregiver arrangements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Plasma cell dyscrasia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.